

Tecadenoson

Catalog No: tcsc0016174



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

204512-90-3

Formula:

$C_{14}H_{19}N_5O_5$

Pathway:

GPCR/G Protein

Target:

Adenosine Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 155 mg/mL (459.49 mM)

Alternative Names:

CVT-510

Observed Molecular Weight:

337.33


Product Description

Tecadenoson (CVT-510) is a selective **A1 adenosine receptor** agonist.

IC50 & Target: Target: A1 adenosine receptor^[1]

In Vitro: In the atrial-paced isolated heart, Tecadenoson is approximately 5 fold more potent to prolong the stimulus-to-His bundle (S-H interval), a measure of slowing AV nodal conduction ($EC_{50}=41$ nM) than to increase coronary conductance ($EC_{50}=200$ nM). At concentrations of Tecadenoson (40 nM) and diltiazem (1 μ M) that causes equal prolongation of S-H interval (~10 ms), diltiazem, but not Tecadenoson, significantly reduces left ventricular developed pressure (LVP) and markedly increases coronary conductance. Tecadenoson shortens atrial ($EC_{50}=73$ nM) but not the ventricular monophasic action potentials (MAP)^[1].

In Vivo: In atrial-paced anaesthetized guinea-pigs, intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval^[1]. Tecadenoson (2, 5, 20 μ g/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson given at 50 μ g/kg causes a significant bradycardia (50% decrease in heart rate at 25 min^[2]).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!